mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype
The Molecular Targets Driving the Revolution Modern incretin-based therapies harness three key hormone receptors that work together to regulate glucose metabolism, appetite, and energy balance: GLP-1R (Glucagon-Like Peptide-1 Receptor) Activated by drugs such as Semaglutide , this receptor stimulates insulin secretion, slows gastric emptying, and promotes satiety, helping reduce food intake and improve blood glucose control
Fibroblast activation protein cleaves and inactivates fibroblast growth factor 21
Insurance coverage is the single biggest factor determining whether a patient can access GLP-1 weight loss treatment
BPC-157 is locally acting - targets injury site through growth factor and fibroblast pathways, dosed in micrograms (250500 mcg), given twice daily
Note that NAION claims are now separate from claims for GI or other types of lawsuits facing these manufacturers
